Key result
Lower LDL levels are linked to the absence of dyspnea in CHF patients on DMT.
Why the study?
The study was conducted to identify biochemical criteria commonly used in general clinical practice for dyspnea in chronic heart failure.
Low LDL levels (≤3.245 mmol/L) are highly specific for the absence of dyspnea in patients with chronic heart failure, suggesting a potential noninvasive marker for CHF compensation.
Answers are grounded in this paper and cite their sources.
Low LDL may mark compensated CHF without dyspnea; leaves open its utility as a noninvasive marker pending validation.
Objective — The goal of our study was to identify biochemical criteria among those most commonly used in general clinical practice for dyspnea in chronic heart failure (CHF). Methods — The study included 594 patients with confirmed CHF. We measured biochemical parameters (levels of creatinine, glucose, low-density lipoprotein [LDL], and C-reactive protein [CRP]) and performed the six-minute walk test (6MWT) before and after disease-modifying therapy (DMT) over the period of 12 months: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor-neprilysin inhibitors (ARNIs), beta blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors. The association of biochemical markers with the presence of dyspnea in patients with CHF was evaluated through correlation analysis and a decision tree. Results — We established that the most closely associated biochemical maker with dyspnea in patients with CHF is the LDL level with cutoff values of 3.245 and 3.266 mmol/L before and after DMT, respectively. High specificity of LDL was demonstrated for recognizing the absence of dyspnea, but critically low sensitivity for the presence Shortness of breath. Conclusion — Low LDL level is associated with an absence of dyspnea in patients with CHF against the background of DMT.
No takes yet. Share an insight, caveat, or question.
Богданова et al. (2025) studied this question. Low LDL levels of 3.245 and 3.266 mmol/L are associated with the absence of dyspnea in patients with chronic heart failure on disease-modifying therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: